Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,totalCashFromFinancingActivities,issuanceOfStock,WC,language,region,quoteType,quoteSourceName,triggerable,currency,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeDataDelayedBy,averageAnalystRating,tradeable,marketState,priceHint,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChange,regularMarketChangePercent,regularMarketTime,regularMarketPrice,regularMarketDayHigh,regularMarketDayRange,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,fullExchangeName,financialCurrency,regularMarketOpen,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,firstTradeDateMilliseconds,shortName,exchange,longName,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,displayName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,GLMD,44999000,25083900,7036000,,-8396000,,-8396000,1376000,0,-8412000,-8412000,,,,,,0,0,8412000,0,16000,,-8396000,-8396000,197829000,7326000,44999000,1379000,52325000,70000,113000,-153008000,108000,7923000,7008000,108000,660000,51665000,43142000,487000,5629000,2176000.0,-174000.0,2169000.0,92000.0,-5462000.0,-7631000.0,10000.0,297000.0,540000.0,-7000.0,,,44657000,en-US,US,EQUITY,Nasdaq Real Time Price,True,USD,-2.3093526,1.794,2.8285713,0.38142872,0.13484854,3.1453624,0.06463766,0.020550147,80519320,-2.3777778,1.7892977,15,0,1.8 - Buy,False,PREPRE,4,0.467286,1630529911,3.225,0.0149999,-0.059999943,-1.8348607,1630526402,3.21,3.29,3.21 - 3.29,3.21,55410,3.27,0.0,0.0,10,31,NasdaqCM,USD,3.22,356489,168742,1.06,0.49302322,2.15 - 6.25,-3.04,-0.4864,2.15,6.25,1628166600,1636551000,1636983000,-1.515,-1.35,-1.39,1394717400000,Galmed Pharmaceuticals Ltd.,NCM,Galmed Pharmaceuticals Ltd.,finmb_114779940,America/New_York,EDT,-14400000,us_market,False,Galmed Pharmaceuticals,2.19,-30.43%,30.90%,6.2500,2.1500,2.8286,3.1454,356.49k,168.74k,25.08M,,19.77M,14.00%,20.41%,467.5k,1.05,2.17%,1.86%,648.68k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-37.85%,-65.75%,,,,,-35.44M,-34.48M,-1.5150,,51.06M,2.04,318k,0.71,7.37,1.79,-30.36M,-17.79M,Value,6578317,Healthcare,18,"Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.",Tel Aviv,972 3 693 8448,1609372800,Israel,http://www.galmedpharma.com,86400,16 Tiomkin Street,972 3 693 8447,Biotechnology
t-1,GLMD,52957000,25083900,7380000,,-8905000,,-8905000,1752000,0,-9132000,-9132000,,,,,,0,0,9132000,0,227000,,-8905000,-8905000,197357000,7420000,52957000,1334000,60377000,70000,113000,-144612000,142000,13385000,7137000,142000,675000,59702000,45420000,784000,5803000,-1643000.0,-1243000.0,-1644000.0,320000.0,6438000.0,-9286000.0,11000.0,28000.0,503000.0,-1000.0,17368000.0,17368000.0,52565000,en-US,US,EQUITY,Nasdaq Real Time Price,True,USD,-2.3093526,1.794,2.8285713,0.38142872,0.13484854,3.1453624,0.06463766,0.020550147,80519320,-2.3777778,1.7892977,15,0,1.8 - Buy,False,PREPRE,4,0.467286,1630529911,3.225,0.0149999,-0.059999943,-1.8348607,1630526402,3.21,3.29,3.21 - 3.29,3.21,55410,3.27,0.0,0.0,10,31,NasdaqCM,USD,3.22,356489,168742,1.06,0.49302322,2.15 - 6.25,-3.04,-0.4864,2.15,6.25,1628166600,1636551000,1636983000,-1.515,-1.35,-1.39,1394717400000,Galmed Pharmaceuticals Ltd.,NCM,Galmed Pharmaceuticals Ltd.,finmb_114779940,America/New_York,EDT,-14400000,us_market,False,Galmed Pharmaceuticals,2.19,-30.43%,30.90%,6.2500,2.1500,2.8286,3.1454,356.49k,168.74k,25.08M,,19.77M,14.00%,20.41%,467.5k,1.05,2.17%,1.86%,648.68k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-37.85%,-65.75%,,,,,-35.44M,-34.48M,-1.5150,,51.06M,2.04,318k,0.71,7.37,1.79,-30.36M,-17.79M,Value,6578317,Healthcare,18,"Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.",Tel Aviv,972 3 693 8448,1609372800,Israel,http://www.galmedpharma.com,86400,16 Tiomkin Street,972 3 693 8447,Biotechnology
t-2,GLMD,44153000,25083900,9025000,,-10277000,,-10277000,1317000,0,-10342000,-10342000,,,,,,0,0,10342000,0,65000,,-10277000,-10277000,179530000,8228000,44153000,763000,52381000,58000,113000,-135707000,272000,6947000,8012000,272000,570000,51811000,43939000,66000,7046000,-1852000.0,1895000.0,-1863000.0,79000.0,-9701000.0,-7838000.0,11000.0,-170000.0,624000.0,-11000.0,17368000.0,17368000.0,43799000,en-US,US,EQUITY,Nasdaq Real Time Price,True,USD,-2.3093526,1.794,2.8285713,0.38142872,0.13484854,3.1453624,0.06463766,0.020550147,80519320,-2.3777778,1.7892977,15,0,1.8 - Buy,False,PREPRE,4,0.467286,1630529911,3.225,0.0149999,-0.059999943,-1.8348607,1630526402,3.21,3.29,3.21 - 3.29,3.21,55410,3.27,0.0,0.0,10,31,NasdaqCM,USD,3.22,356489,168742,1.06,0.49302322,2.15 - 6.25,-3.04,-0.4864,2.15,6.25,1628166600,1636551000,1636983000,-1.515,-1.35,-1.39,1394717400000,Galmed Pharmaceuticals Ltd.,NCM,Galmed Pharmaceuticals Ltd.,finmb_114779940,America/New_York,EDT,-14400000,us_market,False,Galmed Pharmaceuticals,2.19,-30.43%,30.90%,6.2500,2.1500,2.8286,3.1454,356.49k,168.74k,25.08M,,19.77M,14.00%,20.41%,467.5k,1.05,2.17%,1.86%,648.68k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-37.85%,-65.75%,,,,,-35.44M,-34.48M,-1.5150,,51.06M,2.04,318k,0.71,7.37,1.79,-30.36M,-17.79M,Value,6578317,Healthcare,18,"Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.",Tel Aviv,972 3 693 8448,1609372800,Israel,http://www.galmedpharma.com,86400,16 Tiomkin Street,972 3 693 8447,Biotechnology
t-3,GLMD,53656000,25083900,6536000,,-6905000,,-6905000,1054000,0,-7590000,-7590000,,,,,,0,0,7590000,0,685000,,-6905000,-6905000,178938000,6297000,53656000,899000,59953000,58000,113000,-125430000,90000,16648000,6050000,90000,613000,59340000,41937000,642000,5151000,16023000.0,1275000.0,15995000.0,101000.0,11095000.0,-5607000.0,9000.0,27000.0,-114000.0,-28000.0,707000.0,707000.0,53290000,en-US,US,EQUITY,Nasdaq Real Time Price,True,USD,-2.3093526,1.794,2.8285713,0.38142872,0.13484854,3.1453624,0.06463766,0.020550147,80519320,-2.3777778,1.7892977,15,0,1.8 - Buy,False,PREPRE,4,0.467286,1630529911,3.225,0.0149999,-0.059999943,-1.8348607,1630526402,3.21,3.29,3.21 - 3.29,3.21,55410,3.27,0.0,0.0,10,31,NasdaqCM,USD,3.22,356489,168742,1.06,0.49302322,2.15 - 6.25,-3.04,-0.4864,2.15,6.25,1628166600,1636551000,1636983000,-1.515,-1.35,-1.39,1394717400000,Galmed Pharmaceuticals Ltd.,NCM,Galmed Pharmaceuticals Ltd.,finmb_114779940,America/New_York,EDT,-14400000,us_market,False,Galmed Pharmaceuticals,2.19,-30.43%,30.90%,6.2500,2.1500,2.8286,3.1454,356.49k,168.74k,25.08M,,19.77M,14.00%,20.41%,467.5k,1.05,2.17%,1.86%,648.68k,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-37.85%,-65.75%,,,,,-35.44M,-34.48M,-1.5150,,51.06M,2.04,318k,0.71,7.37,1.79,-30.36M,-17.79M,Value,6578317,Healthcare,18,"Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.",Tel Aviv,972 3 693 8448,1609372800,Israel,http://www.galmedpharma.com,86400,16 Tiomkin Street,972 3 693 8447,Biotechnology
